サポート ブログ Antibody Basics: Part 4​ - Antibody formats: Single-Chain Variable Fragments (scFvs)

Antibody Basics: Part 4​ - Antibody formats: Single-Chain Variable Fragments (scFvs)

Biointron 2024-02-19 Read time: 10 mins

Welcome back to Antibody Basics by Biointron, part 4. In this episode, we’ll continue to cover antibody formats, specifically, Single-Chain Variable Fragments (scFvs).

What are single-chain variable fragments?

A form of engineered antibody fragment that have become increasingly important in therapeutic and diagnostic applications due to their unique structural and functional properties. scFvs consist of the variable regions of the heavy (VH) and light (VL) chains of immunoglobulins, connected by a short, flexible linker peptide. This configuration maintains the antigen-binding specificity of conventional antibodies while offering a smaller and versatile structure.

The emergence and evolution of scFvs:

  • 1988: Huston et al., designed an scFv with a single polypeptide connected with a 15 amino acid linker. It showed clear specificity against digoxin.

  • 1990s: Refinement of scFv technology, addressing issues such as stability and solubility. There was increasing interest in potential applications in diagnostics and therapeutics.

  • Early 2000s: Growing use of scFvs in diagnostic applications, including immunoassays and imaging, in addition to therapeutic purposes, especially in cancer targeting.

  • Mid 2000s: Introduction of bispecific scFvs, capable of binding two different antigens simultaneously.

  • 2010s - present: scFvs began entering clinical trials for therapeutic applications, with ongoing research to improve stability, bioavailability, and reduce potential immunogenicity.

Advantages over conventional formats

Traditional antibodies are Y-shaped molecules composed of two identical heavy chains and two identical light chains. Each arm of the Y structure contains a variable region (VH and VL) responsible for antigen recognition. The stem of the Y comprises constant regions that mediate immune responses.

  • Size: Being significantly smaller, scFvs can penetrate tissues more effectively, reaching targets that are inaccessible to full-sized antibodies.

  • Production: scFvs can be produced rapidly and inexpensively in various expression systems, including bacteria, yeast, and mammalian cells.

  • Flexibility and Adaptability: The genetic manipulation of scFvs is simpler, allowing for the creation of customized antibody fragments with specific properties, such as increased stability or altered specificity.

  • Reduced Immunogenicity: The immunogenicity generated by the Fc portion of the antibody is absent in the conventional scFv molecule.

Possible expression systems:

Bacterial: E. coli is the most commonly used host due to its simplicity, rapid growth, low-cost, and high yields up to 10–30% of total cellular protein. However, scFvs produced in bacteria may require proper folding and might lack glycosylation, which is essential for some applications. 

Yeast: Yeasts, like Pichia pastoris, offer a middle ground, providing post-translational modifications and higher yields than bacterial systems. 

Mammalian Cell Lines: Systems like Chinese Hamster Ovary (CHO) cells are used when complex post-translational modifications, such as glycosylation, are necessary for the scFv's function.

Plant: Galeffi et al. successfully produced recombinant scFvs to ErbB-2 with functional expression in stable transgenic tobacco plants.

Insect: Choo et al. expressed a functional recombinant cytolytic immunotoxin, scFv-mel-FLAG, in Spodoptera frugiperda ovarian cells.

Display libraries for scFvs:

Phage Display Libraries: Phage display involves displaying scFvs on the surface of bacteriophages, allowing for the rapid selection of scFvs with high affinity for specific antigens. Immune libraries: Constructed from variable domains of antibody genes of B cells derived from immunized animals e.g. mice, camel, sheep, and humans. Naïve libraries: Derived from nonimmunized donors of B cells constructed from a pool of V-genes of IgM mRNA. These libraries are not biased towards any antigen. Synthetic libraries: Derived from nonimmune sources and prepared synthetically by combining germ line gene sequences together with randomized complementary determining regions (CDRs) that are responsible for antigen binding.

In vitro Ribosomal Display Technology: Ribosome display technology (RDT) is a cell-free system that overcomes many limitations of cell-based methods by producing in vitro protein-mRNA complexes. The method is more efficient when screening large libraries as it does not compromise transformation efficiency, selecting high-affinity combining sites, and eukaryotic cell-free systems, which are capable of post-translational modifications. DNA library of scFv is transcribed and translated in vitro to create the complex for selection on immobilized antigen. The mRNAs specifically bound to the antigen are eluted, followed by reverse transcription, and further selection from the enriched regenerated DNA pool.

Diagnostic applications

ScFvs are diagnostic reagents in several different assay formats, including ELISA tests. They can bind to a variety of molecules, e.g. haptens, proteins, whole pathogens. They have improved stability through protein fusions, e.g. constant light chain domain, leucine zipper dimerization domain (ZIP), Fc fragments, alkaline phosphatase. Detection can be done using secondary antibodies recognizing specific tags fused to the C- or N-terminus of the scFv, e.g. c-myc, E-tag (Pharmacia). Improved protein folding via phage format in ELISA assays - the scFv remains attached to the coat protein of filamentous phage. With new phage display antibody libraries, one can generate a range of scFvs specifically directed against any antigen economically, quickly, and without the bother of immunizing animals and manipulating hybridomas.

Therapeutic applications: Cancer

ScFvs have revolutionized the landscape of targeted therapy, particularly in oncology. Their ability to bind specifically to tumor antigens has led to the development of highly effective, minimally invasive treatments. Examples include:

  • Antibody-Drug Conjugates (ADCs): These are scFvs linked to cytotoxic drugs. The scFv guides the drug directly to cancer cells, improving efficacy and reducing systemic toxicity.

  • Bispecific Antibodies: Comprising two different scFvs, these molecules can engage two different antigens simultaneously, such as a tumor antigen and a T-cell activator, enhancing the immune response against cancer cells.

Only 3 scFv-related therapeutics are approved worldwide, with 3 more in review

  • Blinatumomab (Blincyto): Approved by FDA in 2014. Bispecific tandem scFv targeting CD19 and CD3. Treats acute lymphoblastic leukemia.

  • Brolucizumab (Beovu): Approved by FDA in 2019. scFv targeting VEGF-A. Treats neovascular age-related macular degeneration.

  • Tebentafusp (Kimmtrak): Approved by FDA in 2022. Bispecific scFv-TCR fusion protein targeting gp100 and CD3. Treats metastatic uveal melanoma.

  • Currently in review: Ivonescimab: Bispecific antibody for lung cancer; Tarlatamab: Bispecific T-cell engager for small cell lung cancer; Zanidatamab: Bispecific antibody for biliary tract cancers.

Biointron focuses on antibody discovery, expression, and optimization.


Subscribe to our ブログ

Recent ブログ

The therapeutic efficacy of antibodies is closely related to their ability to recognize and bind specific epitopes on target antigens. Epitopes, or antigenic determinants, are a group of amino acids or other chemical groups that are part of a molecule to which an antibody attaches itself. Epitope characterization can help reveal the mechanism of antibody binding and apply intellectual property (patent) protection for novel antibodies, in addition to designing antibodies with high specificity and minimal cross-reactivity.

Jul 12, 2024
ブログ

Understanding the differences between antibody specificity and selectivity is essential for designing and interpreting antibody-based assays in research for experimental accuracy and data interpretation. Antibody specificity refers to an antibody's ability to recognize and bind to a particular epitope—a unique part of an antigen that elicits an immune response.

Jul 10, 2024
ブログ

Antibody-based assays are essential tools in biomedical research, providing the means to detect, quantify, and visualize specific proteins or antigens within complex biological samples. These assays' efficacy hinges on the antibodies' precise properties. While affinity, avidity, specificity, and selectivity are fundamental to antibody performance, the ultimate impact of these properties is heavily influenced by the experimental context in which the antibody is employed.

Jul 08, 2024
ブログ

Biologics, particularly antibodies, have become indispensable in biomedical research and therapeutic development. Research-use-only (RUO) biologics play a pivotal role in preclinical studies, providing researchers with the necessary tools to explore antibody functions and therapeutic potential in vivo.

Jul 04, 2024
ブログ

お客様の利便性を向上させるためにクッキーを使用しています。詳しくは プライバシーポリシー をご覧ください。